Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic Dexamethasone for Prevention of Cisplatin-Induced Hearing Loss
NCT01372904Phase 4Completed
- Sponsor
- Meir Medical Center
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexamethasone in cisplatin-induced ototoxicity (CIOT), sponsored by Meir Medical Center. Primary endpoints: Protective effect of IT dexamethasone on cisplatin-induced hearing loss at 2 years, Pure tone average thresholds for 500-3000 and 4000-8000 Hz and 1 more. Started Jun 2011; status: completed.
02
Drugs
dexamethasone
03
Conditions
cisplatin-induced ototoxicity (CIOT)
Beyond the preview
Go deeper on NCT01372904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01372904.